A Zepbound KwikPen at retail runs $1,086 per month. A Wegovy oral tablet through NovoCare Direct runs $149. Same drug class, eight times the price. If you have Googled “GLP-1 cost” and ended up with a dozen different numbers, that gap is why.
The spread is real, and where you land inside it depends on four levers: which drug you take, whether insurance covers it (and for what reason), which channel you buy through, and which dose you actually need.
This guide walks each lever. We cover 2026 sticker prices for every branded GLP-1, the three major price-reduction paths (insurance, manufacturer savings cards, and direct cash-pay programs), the new federal pricing rolling out July 1, 2026 (the Medicare GLP-1 Bridge and TrumpRx), compounded tirzepatide and semaglutide as a legitimate budget path, the international question (and why it is not the deal it looks like), the hidden fees nobody quotes, microdosing as a long-term cost-reduction strategy, the stop-and-restart math that changes everything, the cost-effectiveness debate, and a decision tree that maps your situation to the cheapest legitimate channel.
By the end you will know roughly what you should be paying in 2026, which channel you should be in, and which of the new programs you actually qualify for.
2026 Sticker Prices by Drug
Prices vary by dose and channel, but here is what each branded GLP-1 actually costs in 2026.
- Wegovy injectable (semaglutide, weight loss). Retail around $1,349/mo. NovoCare Direct charges $199/mo for the first two fills (0.25 mg and 0.5 mg) through June 30, 2026, then $349/mo for all doses up to 2.4 mg, or $399/mo for Wegovy HD 7.2 mg.
- Wegovy pill (oral semaglutide). $149/mo for the 1.5 mg dose. The 4 mg dose is also $149/mo through August 31, 2026, then $199/mo. Currently the cheapest branded path in the entire market.
- Ozempic (semaglutide, T2D-labeled). Retail around $1,000/mo. NovoCare Direct charges $199/mo for the first two fills, $349/mo ongoing for 0.25 mg to 1 mg, and $499/mo for the 2 mg dose.
- Zepbound vial (tirzepatide, weight loss). LillyDirect charges $299/mo for the 2.5 mg starter, $399/mo for 5 mg, and $449/mo flat for every higher dose (7.5 mg through 15 mg). Program runs through at least December 2026.
- Zepbound KwikPen. Retail $1,086/mo. GoodRx coupon brings it to roughly $995. LillyDirect lists a self-pay KwikPen starter at $299/mo. The vial format runs 30 to 40 percent cheaper than the pen for the same drug.
- Mounjaro (tirzepatide, T2D-labeled). Retail $1,000 to $1,200/mo for four single-use pens. With commercial insurance plus the Eli Lilly savings card plus a type 2 diabetes diagnosis, it drops to $25/mo.
- Rybelsus (oral semaglutide, T2D-labeled). Retail $900 to $1,200/mo for 30 daily tablets. The only branded oral GLP-1 approved for T2D. Not included in the Medicare GLP-1 Bridge.
If you are paying cash, the two cheapest branded paths are the Zepbound vial through LillyDirect and the Wegovy pill through NovoCare. Everything else costs more unless you can layer insurance or a savings card on top.
When Insurance Covers GLP-1 and What It Takes to Get Approved
Insurance treats GLP-1s very differently depending on what you are using them for, and that difference is the single biggest driver of what you will pay.
For type 2 diabetes (Ozempic, Mounjaro, Rybelsus), coverage is broad and copays often land between $25 and $100. For weight loss (Wegovy, Zepbound), coverage is uneven. Many commercial plans cover with a prior authorization. Many others exclude weight-loss drugs entirely. Medicare historically did not cover GLP-1s for weight loss at all. The July 2026 Bridge changes that.
Most plans that do cover weight-loss GLP-1s require BMI 30+, or BMI 27+ with a qualifying comorbidity (T2D, hypertension, dyslipidemia, sleep apnea, or established cardiovascular disease). Many also require step therapy, meaning documented failure of a cheaper intervention first.
If you are gearing up for a prior authorization, assemble this before you call:
- Current BMI documented in your medical record
- Comorbidity diagnoses with ICD codes
- Prior weight-loss attempts: medications tried, doses, dates, outcomes
- Lifestyle intervention history: diet programs, exercise programs, dates
- Letter of medical necessity from your prescriber addressing the exact PA language your plan uses
- For step therapy: which step-1 medications were tried, at what dose, for how long, and why they failed
Here is the number to remember if you get denied. 82% of prior authorization denials are overturned on appeal, but fewer than 11% of patients ever file one. If your plan denies the first request, file an internal appeal within 180 days. The math is on your side.
Manufacturer Savings Cards: Who They Actually Help
A Mounjaro savings card can drop your monthly out-of-pocket cost to $25 if you check three boxes. Most articles list these cards as universally available. They are not.
The three boxes:
- You have commercial insurance. Medicare, Medicaid, VA, and TRICARE patients are explicitly excluded across every major manufacturer card.
- For Mounjaro specifically, your prescription is written for type 2 diabetes. The Mounjaro card is not available for off-label weight-loss use.
- You are not stacking the card with GoodRx or another third-party discount coupon at the same fill. They cannot be combined.
What is on offer right now: a Mounjaro savings card at $25/mo for commercially insured T2D patients, a Zepbound card for commercially insured weight-loss patients (savings vary by plan), a Wegovy savings card through NovoCare for commercial enrollees, and an Ozempic NovoCare card. Government-insured patients use the Medicare GLP-1 Bridge or LillyDirect/NovoCare cash pricing instead.
The stacking trap worth naming. If you have a Mounjaro savings card, do not let the pharmacy tech run a GoodRx coupon on the same prescription. They cannot legally combine, and the manufacturer card is almost always the cheaper of the two. Check the receipt. If you see a GoodRx discount applied alongside the manufacturer card, ask the pharmacist to reprocess.
Buying Direct: LillyDirect, NovoCare, and the New Cash Channels
In 2024 the cheapest branded path was a manufacturer savings card layered on commercial insurance. In 2026 the cheapest branded path for self-pay patients is the manufacturer-direct vial or pill program. These channels bypass pharmacy benefit managers entirely.
Three programs to know:
- NovoCare Direct. Covers Wegovy injectable, Wegovy pill, and Ozempic. Intro pricing is $199/mo for the first two fills of the injectables (through June 30, 2026), then $349/mo ongoing. The Wegovy pill is $149/mo for 1.5 mg and 4 mg (the 4 mg promo runs through August 31, 2026, then $199). Self-pay only.
- LillyDirect Zepbound Vial Program. $299/mo for the 2.5 mg starter, $399/mo for 5 mg, $449/mo flat for every higher dose. Vials require BD 31G syringes and bacteriostatic water, neither included. The vial format runs 30 to 40 percent cheaper than the KwikPen for the same drug at the same dose.
- TrumpRx DTC portal. Live in 2026. Approximately $350/mo for injectable Wegovy or Zepbound; intro doses at $199/mo. Non-Medicare patients use TrumpRx directly. Medicare patients route to the Bridge (next section).
The trade-off worth naming. Vials and oral tablets are cheaper, but vials require self-administration prep (syringes, bacteriostatic water, alcohol pads, sharps disposal), and oral semaglutide has stricter dosing rules (empty stomach, full glass of water, wait 30 minutes). The KwikPen costs more because you are paying for the auto-injector convenience. If you are comfortable drawing up a dose from a vial, you can cut your monthly drug cost roughly in half.
The Medicare GLP-1 Bridge and TrumpRx: What Changed July 2026
Starting July 1, 2026, eligible Medicare Part D enrollees pay $50/mo for Wegovy injectable, Wegovy pill, Zepbound KwikPen, or Foundayo. This is the first time Medicare has covered GLP-1s for weight loss.
There are three eligibility tiers. You qualify if you have:
- BMI 35+, or
- BMI 30+ with heart failure, uncontrolled hypertension, or chronic kidney disease, or
- BMI 27+ with pre-diabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease.
You also have to be enrolled in a Medicare Part D plan, and your prescriber has to write for one of the four covered drugs.
Then the gotchas. First, the $50 copay does NOT count toward your Part D deductible or the $2,100 annual out-of-pocket cap, so it sits on top of all your other drug spend. Second, Medicare Extra Help (the low-income subsidy) patients are excluded from the Bridge copay structure, which is the opposite of how most Medicare programs work. Third, the Bridge sunsets December 31, 2027. CMS has signaled the BALANCE Model could take over in 2028, but it is not guaranteed. Fourth, Ozempic and Mounjaro are not covered. KFF Health News has done the most detailed reporting on these gaps.
TrumpRx is the broader Most Favored Nation portal the Bridge sits inside. Non-Medicare patients use TrumpRx to access $350/mo injectable Wegovy or Zepbound directly. Medicare patients route through the Bridge. The negotiated Medicare price under the MFN deal is $245/mo, and the $50 copay reflects the federal subsidy on top of that.
The bigger structural shift starts January 2027, when Inflation Reduction Act price negotiation begins on GLP-1s. Projected cuts of 40 to 60 percent would take $1,349 retail down to roughly $540 to $810/mo for branded weight-loss drugs.
Compounded Tirzepatide and Semaglutide: The Narrow but Real Path
Compounded tirzepatide and semaglutide can still be prescribed in 2026, but the legal pathway is much narrower than it was during the 2024 shortage boom. For the right patient it remains the single cheapest legitimate GLP-1 path.
The legal landscape. In October 2024 the FDA resolved the tirzepatide shortage, which removed the broad 503B bulk-compounding justification telehealth platforms had been operating under. In May 2026 the FDA moved to permanently close 503B bulk compounding of GLP-1 APIs. 503A patient-specific compounding remains legal, but only with (a) a documented allergy to a commercial product’s inactive ingredient, or (b) prescriber documentation that the commercial product cannot meet a specific clinical need. Cost savings alone no longer qualifies. More than 30 companies received FDA warning letters in early 2026; Hims exited the market.
The pricing where it is still legally available. Compounded tirzepatide through 503A telehealth runs $150 to $600/mo, with most platform pricing $299 to $499/mo. Compounded semaglutide runs $150 to $300/mo. Pricing is typically flat across doses, which matters: branded vial pricing scales with dose. Compounded is one flat number.
Who compounded is right for: patients with a documented 503A clinical justification, patients comfortable with non-FDA-approved formulations, and patients who want flat-rate, dose-independent pricing they cannot get from a branded channel.
Who it is not right for: patients who can comfortably afford LillyDirect or NovoCare cash pricing, Medicare and Medicaid patients (use the Bridge), and patients with the standard GLP-1 contraindications (personal or family history of medullary thyroid carcinoma, MEN 2, prior pancreatitis, or active pregnancy).
If compounded sounds like the right fit, work with a telehealth platform that operates inside the narrowed 503A pathway. Compounded is not a consolation prize. For a meaningful slice of patients it is simply the right channel.
[CTA: Compare compounded GLP-1 telehealth options →]
Importing From Mexico, Canada, or India: Why It Looks Cheap and Why It Is Not
European branded GLP-1 prices run $83 to $144 per month. That is roughly a quarter of what Americans pay. The price gap is real and it is the reason TikTok is full of videos about $80 semaglutide from Mexico City.
The FDA rule, stated cleanly. The personal-importation policy allows up to a 90-day supply of a non-FDA-approved drug for personal use in limited circumstances, specifically serious conditions where no adequate FDA-approved treatment is available in the US. The policy was not designed as a cost-arbitrage mechanism, and FDA officials have said so directly. In February 2026, FDA Commissioner Marty Makary announced an upcoming enforcement crackdown specifically targeting imported GLP-1 active pharmaceutical ingredients intended for non-FDA-approved compounded drugs.
The risks the TikToks do not mention. The Partnership for Safe Medicines has documented counterfeit GLP-1 drugs in 12 or more countries, with hospitalizations and at least one reported UK death from black-market “skinny jabs.” Cold chain failure during international shipping is a real and underreported quality issue (GLP-1s are temperature-sensitive biologics and lose potency when warm). Customs seizure is common for any package flagged at the border, which means your $400 order can disappear with no refund.
There is a real price gap. It does not translate into a safe DIY path for most US patients. The cash channels we covered earlier (LillyDirect vials, NovoCare pills, compounded 503A telehealth) hit roughly the same price tier with FDA-traceable supply and no customs risk.
The Hidden Costs Nobody Quotes
A $299/mo Zepbound vial is not actually $299/mo. Here is what you are also paying for.
- Telehealth subscription / membership fee. $50 to $150/mo. Covers virtual consults and support. Almost never includes medication.
- Lab work at intake and periodically. $50 to $100. Some platforms include it; many do not.
- Syringes for vial users. $10 to $20/mo for a 100-count box of BD Ultra-Fine 31G.
- Bacteriostatic water (compounded vials only). $5 to $10/mo.
- Alcohol prep pads and sharps disposal. $5 to $10/mo.
- Shipping. $15 to $30/mo. Read the fine print.
- Consultation fees if you do not proceed. Up to $80.
Two true all-in examples.
LillyDirect Zepbound vial path: $299 medication plus ~$30 in supplies = $329/mo all-in. No telehealth subscription required because LillyDirect is direct from the manufacturer.
Compounded telehealth tirzepatide path: $299 medication plus $100 telehealth subscription plus $30 supplies plus $20 shipping = $449/mo all-in. The $150 gap is invisible on the headline price.
Compare all-in, not headline. A flat-rate telehealth program advertised at $399/mo that includes consults, shipping, and lab work can easily beat a $299 medication price that quietly tacks on $150 in subscription and shipping fees. Ask any platform for the all-in number before you enroll.
Microdosing as a Cost-Reduction Strategy
A standard tirzepatide titration starts at 2.5 mg weekly and climbs to 15 mg over five months. On most pricing models, cost rises with each step. Holding at 2.5 mg or 5 mg long-term cuts your annual cost meaningfully without giving up most of the clinical benefit.
The clinical anchor. In one published semaglutide study, participants at 1 mg weekly lost an average of 16 percent of body weight over 64 weeks, nearly matching the 2.4 mg dose when paired with lifestyle changes. The dose-response curve is not linear; most of the appetite-regulating effect comes online at sub-titration doses, and higher doses primarily extract additional weight loss with steeper side effect costs.
The cost math. Compounded tirzepatide at a 2.5 mg microdose typically runs $250 to $350/mo. The same product at full maintenance dose runs $400 to $450 or more. Over a year, that is $1,800 to $2,400 saved.
Trade-offs. Slower weight loss. Fewer side effects, which often translates into better long-term adherence. Lower monthly cost. Microdosing is off-label, so it requires a prescriber willing to support the protocol, and dosing accuracy matters more at low volumes.
Microdosing fits patients who hit their goal weight at a sub-titration dose and want to maintain there, patients who tolerate low doses well, and patients willing to trade speed for cost. Not every clinician will support it; compounded telehealth providers are typically more open because their dose delivery is more flexible.
What Happens If You Stop and Why That Changes the Math
The cost question is not really what one month costs. It is what ten years costs, because GLP-1s generally require ongoing use to keep the weight off.
The trial data is consistent.
- SURMOUNT-4. Patients who stopped tirzepatide regained more than 50 percent of their lost weight within 52 weeks.
- STEP-10. More than 40 percent of semaglutide weight loss was regained within 28 weeks of stopping.
- STEP-4. Participants switched to placebo after a 20-week run-in showed immediate weight regain.
Real-world data from Hamlet Gasoyan, PhD, published in AJMC suggests regain in clinical practice is slightly slower than the randomized-withdrawal trials imply. The direction is the same; the timeline is more gradual.
The cost translation. At $349/mo on NovoCare Wegovy or $329/mo all-in on a LillyDirect Zepbound vial, ongoing use is roughly $4,200/year. Over five years, $21,000+. Over ten years, $42,000+. That is the number to budget against, not one month at $329.
Two practical implications. First, cheaper monthly programs (compounded, microdose, LillyDirect vial) compound dramatically over a five- to ten-year horizon. A $150/mo difference is real money at one year and life-changing at ten. Second, some patients can transition to a maintenance microdose to cut the long-horizon cost without stopping entirely.
Is It Worth It? The Cost-Effectiveness Debate
UChicago Medicine ran the most-cited cost-effectiveness analysis on GLP-1s, and the headline is uncomfortable. The accepted threshold is $100,000 per quality-adjusted life year (QALY). At current list prices, tirzepatide needs roughly a 30 percent price cut and semaglutide needs an 80 percent cut to clear that bar.
The Medicare-scale numbers are starker. At list prices, projected Medicare net spending on GLP-1s runs $47.7 billion over a decade. Under Most Favored Nation pricing at $245/mo, that drops to roughly $18 billion. The researchers framed it directly: “Insurers and policymakers aren’t just asking, Is this a good treatment? They’re asking, What will this do to our budget?”
That is the institutional view. The individual view is different. For an insurer evaluating 68 million Medicare lives at list price, the QALY math is brutal. For a patient paying $329/mo all-in for a Zepbound vial program, you are comparing your monthly cost against your personal risk of cardiovascular events, type 2 diabetes progression, joint replacement, and the quality-of-life cost of living at a weight you find unsustainable. The SURMOUNT and STEP outcomes give individuals good reason to pay a price that does not yet make sense for federal budgets.
The budget-impact debate is the reason 2026 prices are falling and 2027 IRA negotiation is on track to drop them further. It is not a reason to skip the medication if the math works for you.
Your Cheapest Legitimate Path, By Situation
You have read the levers. Here is which one to pull. Five scenarios. Pick the highest tier you qualify for.
- Commercially insured, type 2 diabetes diagnosis. Mounjaro with the Eli Lilly savings card. $25/mo for up to a 3-month supply when your insurance approves the script. Do not stack with GoodRx. If your script is for off-label weight loss, drop to scenario 2.
- Commercially insured, weight loss only, BMI 30+ (or 27+ with a comorbidity). Submit a Wegovy or Zepbound prior authorization with the checklist from section 3. If approved, layer the manufacturer savings card. If denied, appeal (82 percent overturn rate). If your plan excludes weight-loss drugs entirely, drop to scenario 4.
- Medicare Part D, clears one of the three Bridge tiers, not on Extra Help. Medicare GLP-1 Bridge starting July 1, 2026. $50/mo copay for Wegovy injectable, Wegovy pill, Zepbound KwikPen, or Foundayo. Budget for the December 31, 2027 sunset.
- Uninsured, weight-loss exclusion, or no T2D diagnosis. LillyDirect Zepbound vial at $299 to $449/mo plus ~$30 in supplies, OR NovoCare Wegovy injectable at $199 intro / $349 ongoing, OR NovoCare Wegovy pill at $149/mo (currently the cheapest branded path in the market).
- Budget-constrained, comfortable with non-FDA-approved formulations, can document a clinical justification. Compounded tirzepatide or semaglutide via a 503A telehealth provider, $250 to $499/mo flat. A microdose protocol can cut that further.
The order above is roughly cheapest to most expensive within each category.
GLP-1 Cost FAQ
How much does a GLP-1 cost per month without insurance in 2026?
Cash prices range from $149 to $1,300/mo depending on the drug and the channel. The cheapest current self-pay paths are the Wegovy pill at $149/mo through NovoCare, the LillyDirect Zepbound vial starting at $299/mo, and the NovoCare Wegovy injectable at $199/mo for the first two fills then $349/mo ongoing. TrumpRx runs around $350/mo for injectable Wegovy or Zepbound.
Does Medicare cover GLP-1 weight loss drugs?
Yes, starting July 1, 2026, through the Medicare GLP-1 Bridge. The copay is $50/mo for Wegovy injectable, Wegovy pill, Zepbound KwikPen, or Foundayo if you are enrolled in Part D, meet one of three BMI/comorbidity tiers, and are not on Extra Help. The Bridge program runs through December 31, 2027. The copay does not count toward your Part D deductible or the $2,100 OOPM cap.
Can I still get compounded tirzepatide or semaglutide in 2026?
Yes, but only through 503A patient-specific compounding, and only with a documented allergy to a commercial product’s inactive ingredient or prescriber documentation that the commercial product cannot meet a specific clinical need. Cost savings alone no longer qualifies as a justification. 503B bulk compounding of GLP-1 APIs is fully prohibited as of 2026.
Can I use a GoodRx coupon and a manufacturer savings card at the same time?
No. Manufacturer savings cards cannot be combined with GoodRx or any third-party discount coupon on the same fill. Government-insured patients (Medicare, Medicaid, VA, TRICARE) cannot use manufacturer savings cards at all. If you have both options, the manufacturer card is almost always the cheaper one to apply.
What happens to my weight if I stop taking a GLP-1?
Clinical trial data shows substantial regain. SURMOUNT-4: more than 50 percent of tirzepatide weight loss regained within 52 weeks of stopping. STEP-10: more than 40 percent of semaglutide weight loss regained within 28 weeks. Real-world data from AJMC suggests regain is slightly slower in practice than in trials, but the directional trend is the same. Budget for ongoing use.
What does insurance prior authorization actually require?
Most commercial plans require BMI 30+ (or 27+ with a qualifying comorbidity like T2D, hypertension, dyslipidemia, sleep apnea, or cardiovascular disease), documentation of prior weight-loss attempts and lifestyle interventions, and sometimes step therapy. If denied, file an internal appeal within 180 days. 82 percent of PA denials are overturned on appeal, but fewer than 11 percent of patients ever file one.
Is microdosing a legitimate way to cut GLP-1 costs?
Off-label and experimental, but supported by dose-response data. A 1 mg semaglutide study showed 16 percent body weight loss over 64 weeks, nearly matching the full 2.4 mg dose when paired with lifestyle changes. Compounded tirzepatide at a 2.5 mg microdose runs $250 to $350/mo versus $400 to $450 or more at full titration. Requires medical supervision because dosing accuracy matters more at low volumes.